CASI Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CASI) $5.59 0.00 (0.00%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$5.38▼$5.6850-Day Range$2.00▼$5.8552-Week Range$1.45▼$5.94Volume22,379 shsAverage VolumeN/AMarket Capitalization$74.46 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability CASI Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside114.7% Upside$12.00 Price TargetShort InterestHealthy2.52% of Float Sold ShortDividend StrengthN/ASustainability-1.50Upright™ Environmental ScoreNews Sentiment0.96Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.37 out of 5 starsMedical Sector246th out of 957 stocksBiological Products, Except Diagnostic Industry34th out of 159 stocks 3.5 Analyst's Opinion Consensus RatingCASI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.00, CASI Pharmaceuticals has a forecasted upside of 114.7% from its current price of $5.59.Amount of Analyst CoverageCASI Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.52% of the float of CASI Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCASI Pharmaceuticals has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in CASI Pharmaceuticals has recently decreased by 33.01%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCASI Pharmaceuticals does not currently pay a dividend.Dividend GrowthCASI Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCASI Pharmaceuticals has received a 62.54% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Melphalan" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for CASI Pharmaceuticals is -1.50. Previous Next 3.3 News and Social Media Coverage News SentimentCASI Pharmaceuticals has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for CASI Pharmaceuticals this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for CASI on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows4 people have added CASI Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CASI Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders21.24% of the stock of CASI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 14.62% of the stock of CASI Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of CASI Pharmaceuticals is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CASI Pharmaceuticals is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCASI Pharmaceuticals has a P/B Ratio of 2.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About CASI Pharmaceuticals Stock (NASDAQ:CASI)CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; and CID-103, a human IgG1 anti-CD38 monoclonal antibody. The company has licensing agreements with Juventas Biotechnology (Tianjin) Co., Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.Read More CASI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CASI Stock News HeadlinesNovember 29, 2023 | americanbankingnews.comCASI Pharmaceuticals (NASDAQ:CASI) Earns Hold Rating from Analysts at StockNews.comNovember 15, 2023 | markets.businessinsider.comHC Wainwright & Co. Maintains Buy Rating for CASI Pharmaceuticals: Here's What You Need To KnowDecember 3, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 14, 2023 | markets.businessinsider.comCASI Pharmaceuticals Posts Narrower Loss In Q3November 14, 2023 | msn.comCASI Pharmaceuticals GAAP EPS of -$0.35, revenue of $8.84MNovember 14, 2023 | finance.yahoo.comCASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATESNovember 8, 2023 | markets.businessinsider.comCASI : Juventas' CNCT 19 Approved In China For R/R B-cell Acute Lymphoblastic Leukemia TreatmentAugust 14, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for CASI Pharmaceuticals (CASI)December 3, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.August 11, 2023 | markets.businessinsider.comCASI Pharmaceuticals, Inc. Q2 Loss WidensAugust 11, 2023 | msn.comCASI Pharmaceuticals GAAP EPS of -$0.77, revenue of $9.82MAugust 11, 2023 | finance.yahoo.comCASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATESAugust 10, 2023 | msn.comIonis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates (Revised)August 10, 2023 | msn.comProPhase Labs, Inc. (PRPH) Reports Q2 Loss, Lags Revenue EstimatesAugust 1, 2023 | finance.yahoo.comMundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI PharmaceuticalsJuly 20, 2023 | finance.yahoo.comCleave Therapeutics Announces Acquisition of Clinical and Preclinical AssetsJuly 20, 2023 | finance.yahoo.comCASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339July 10, 2023 | finance.yahoo.comSwitch Therapeutics Appoints Douglas Fambrough, Ph.D., to Board of DirectorsJune 28, 2023 | finance.yahoo.comCASI - CASI Pharmaceuticals, Inc.May 28, 2023 | finance.yahoo.comWe Think CASI Pharmaceuticals (NASDAQ:CASI) Needs To Drive Business Growth CarefullyMay 17, 2023 | finanznachrichten.deCASI Pharmaceuticals, Inc. Announces First Quarter 2023 Financial ResultsMay 17, 2023 | finance.yahoo.comCASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTSMay 3, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH) and Cytosorbents (CTSO)April 26, 2023 | msn.comCASI Pharmaceuticals GAAP EPS of -$3.01 misses by $2.64, revenue of $43.12M beats by $32.31MApril 26, 2023 | finance.yahoo.comCASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022April 26, 2023 | finance.yahoo.comCASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTSApril 17, 2023 | finance.yahoo.comImproved Revenues Required Before CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Stock's 114% Jump Looks JustifiedSee More Headlines Receive CASI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CASI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/11/2023Today12/03/2023Fiscal Year End12/31/2023Next Earnings (Estimated)4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CASI CUSIPN/A CIK895051 Webwww.casipharmaceuticals.com Phone861065086063Fax301-315-2437Employees224Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+114.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,010,000.00 Net Margins-95.24% Pretax Margin-87.15% Return on Equity-110.90% Return on Assets-47.81% Debt Debt-to-Equity RatioN/A Current Ratio4.91 Quick Ratio4.17 Sales & Book Value Annual Sales$43.11 million Price / Sales1.73 Cash FlowN/A Price / Cash FlowN/A Book Value$2.16 per share Price / Book2.59Miscellaneous Outstanding Shares13,320,000Free Float10,492,000Market Cap$74.46 million OptionableNot Optionable BetaN/A 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Wei-Wu He Ph.D. (Age 58)Chairman & CEO Comp: $565.36kDr. Wei Zhang Ph.D. (Age 63)President Comp: $1.13MDr. Alexander A. Zukiwski M.D. (Age 66)Executive VP & Chief Medical Officer Comp: $514.79kMs. Kun Qian (Age 41)VP & Global Controller Ms. Chunhua Wang (Age 51)Chief Operating Officer Ms. Wei Gao (Age 42)General Counsel Dr. James E. Goldschmidt Ph.D.Chief Business Development OfficerMr. Fuqiang Zhang (Age 54)Chief Commercial Officer Ms. Amanda CuiVP & Global ControllerMore ExecutivesKey CompetitorsNKGen BiotechNYSE:NKGNAtara BiotherapeuticsNASDAQ:ATRACidara TherapeuticsNASDAQ:CDTXSangamo TherapeuticsNASDAQ:SGMOIkena OncologyNASDAQ:IKNAView All Competitors CASI Stock Analysis - Frequently Asked Questions Should I buy or sell CASI Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CASI shares. View CASI analyst ratings or view top-rated stocks. What is CASI Pharmaceuticals' stock price target for 2024? 1 Wall Street analysts have issued 12-month price targets for CASI Pharmaceuticals' shares. Their CASI share price targets range from $12.00 to $12.00. On average, they anticipate the company's stock price to reach $12.00 in the next year. This suggests a possible upside of 114.7% from the stock's current price. View analysts price targets for CASI or view top-rated stocks among Wall Street analysts. How have CASI shares performed in 2023? CASI Pharmaceuticals' stock was trading at $1.79 at the start of the year. Since then, CASI stock has increased by 212.3% and is now trading at $5.59. View the best growth stocks for 2023 here. Are investors shorting CASI Pharmaceuticals? CASI Pharmaceuticals saw a decline in short interest in November. As of November 15th, there was short interest totaling 151,200 shares, a decline of 33.0% from the October 31st total of 225,700 shares. Based on an average daily volume of 30,600 shares, the short-interest ratio is currently 4.9 days. Approximately 2.5% of the company's shares are short sold. View CASI Pharmaceuticals' Short Interest. When is CASI Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024. View our CASI earnings forecast. How were CASI Pharmaceuticals' earnings last quarter? CASI Pharmaceuticals, Inc. (NASDAQ:CASI) announced its earnings results on Friday, August, 11th. The biotechnology company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.50) by $0.27. The biotechnology company earned $9.82 million during the quarter, compared to analyst estimates of $10.09 million. CASI Pharmaceuticals had a negative trailing twelve-month return on equity of 110.90% and a negative net margin of 95.24%. When did CASI Pharmaceuticals' stock split? Shares of CASI Pharmaceuticals reverse split before market open on Wednesday, June 1st 2022. The 1-10 reverse split was announced on Wednesday, June 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of CASI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other CASI Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), Caladrius Biosciences (CLBS), Overstock.com (OSTK), Riot Platforms (RIOT), Boeing (BA), Enphase Energy (ENPH), Catalyst Pharmaceuticals (CPRX), Pure Storage (PSTG) and QUALCOMM (QCOM). Who are CASI Pharmaceuticals' major shareholders? CASI Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include James Huang, Weihao Xu and Wei-Wu He. View institutional ownership trends. How do I buy shares of CASI Pharmaceuticals? Shares of CASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:CASI) was last updated on 12/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CASI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.